参考文献/References:
[1]Dunlay SM,Roger VL,Redfield MM. Epidemiology of heart failure with preserved ejection fraction[J]. Nat Rev Cardiol,2017,14(10):591-602. [2]Brown DA,Perry JB,Allen M E,et al. Expert consensus document:mitochondrial function as a therapeutic target in heart failure[J]. Nat Rev Cardiol,2017,14(4):238-250. [3]Csepe TA,Kilic A. Advancements in mechanical circulatory support for patients in acute and chronic heart failure[J]. J Thorac Dis,2017,9(10):4070-4083. [4]胡盛寿,高润霖,刘力生,等. 《中国心血管病报告2018》概要[J]. 中国循环杂志,2019,34(3):209-220. [5]Tayal U,Prasad S,Cook SA. Genetics and genomics of dilated cardiomyopathy and systolic heart failure[J]. Genome Med,2017,9(1):20. [6]Reza N,Owens AT. Advances in the genetics and genomics of heart failure[J]. Curr Cardiol Rep,2020,22(11):132. [7]Syvänen AC. Accessing genetic variation:genotyping single nucleotide polymorphisms[J]. Nat Rev Genet,2001,2(12):930-942. [8]Bohm M,Ewen S,Mahfoud F. Renal denervation for chronic heart failure:background and pathophysiological rationale[J]. Korean Circ J,2017,47(1):9-15. [9]Luzum JA,English JD,Ahmad US,et al. Association of genetic polymorphisms in the beta-1 adrenergic receptor with recovery of left ventricular ejection fraction in patients with heart failure[J]. J Cardiovasc Transl Res,2019,12(4):280-289. [10]Johnson AE,Hanley-Yanez K,Yancy CW,et al. Adrenergic polymorphisms and survival in African Americans with heart failure:results from A-HeFT[J]. J Card Fail,2019,25(7):553-560. [11]Huang J,Li C,Song Y,et al. ADRB2 polymorphism Arg16Gly modifies the natural outcome of heart failure and dictates therapeutic response to beta-blockers in patients with heart failure[J]. Cell Discov,2018,4:57. [12]张博,李平,刘广交,等. 慢性充血性心力衰竭患者的ACE基因多态性及预后的研究[J]. 中国医药科学,2018,8(5):207-210. [13]Bahramali E,Rajabi M,Jamshidi J,et al. Association of ACE gene D polymorphism with left ventricular hypertrophy in patients with diastolic heart failure:a case-control study[J]. BMJ Open,2016,6(2):e010282. [14]Bai YY,Wang L,Hu SS,et al. Association of angiotensin-converting enzyme I/D polymorphism with heart failure:a meta-analysis[J]. Mol Cell Biochem,2012,361(1-2):297-304. [15]Starzhynska O,Zhebel V,Blanar O. Polymorphism angiotensin Ⅱ type 1 receptor gene and endothelial dysfunction in patients with essential hypertension and congestive heart failure[J]. Can J Cardiol,2012,28(5):S115. [16]Moe SM,Long J,Schwantes-An TL,et al. Angiotensin-related genetic determinants of cardiovascular disease in patients undergoing hemodialysis[J]. Nephrol Dial Transplant,2019,34(11):1924-1931. [17]Zhang JA,Li JR,Qiao YJ. Association of AGTR1 gene A1166C polymorphism with the risk of heart failure:a meta-analysis[J].Genet Mol Res,2015,14(3):9163-9170. [18]Dhaun N,Webb DJ. Endothelins in cardiovascular biology and therapeutics[J]. Nat Rev Cardiol,2019,16(8):491-502. [19]Douvaras P,Antonatos DG,Kekou K,et al. Association of VEGF gene polymorphisms with the development of heart failure in patients after myocardial infarction[J]. Cardiology,2009,114(1):11-18. [20]Wang Y,Zhang Y,An T,et al. ErbB4 gene polymorphism is associated with the risk and prognosis of congestive heart failure in a northern han Chinese population[J]. J Card Fai,2016,22(9):700-709. [21]Colombo MG,Ciofini E,Paradossi U,et al. ET-1 Lys198Asn and ET(A) receptor H323H polymorphisms in heart failure.A case-control study[J]. Cardiology,2006,105(4):246-252. [22]Oliveira RVM,Albuquerque FN,Duque GS,et al. Heart failure and endothelial nitric oxide synthase G894T gene polymorphism frequency variations within ancestries[J]. Nitric oxide,2018,73:60-65. [23]Fares F,Smith Y,Azzam N,et al. The 894G allele of the endothelial nitric oxide synthase 3 (eNOS) is associated with atrial fibrillation in chronic systolic heart failure[J]. J Atr Fibrillation,2012,5(4):757. [24]Goppe ES,Maltese PE,Chernova A,et al. Glu298Asp polymorphism in the NOS3 gene is not associated with susceptibility to chronic heart failure in a Russian population[J]. Genet Mol Res,2019,18(1):7. [25]Shirazi LF,Bissett J,Romeo F,et al. Role of inflammation in heart failure[J]. Curr Atheroscler Rep,2017,19(6):27. [26]Markousis-Mavrogenis G,Tromp J,Ouwerkerk W,et al. The clinical significance of interleukin-6 in heart failure:results from the BIOSTAT-CHF study[J]. Eur J Heart Fail,2019,21(8):965-973. [27]Hansen PR,Nelveg-Kristensen KE,Rasmussen HB,et al. Prognostic role of genetic polymorphisms of the interleukin-6 signaling pathway in patients with severe heart failure[J]. Pharmacogenomics J,2019,19(5):428-437. [28]Chen Y,Liu W,Wang Y,et al. Casein Kinase 2 Interacting Protein-1 regulates M1 and M2 inflammatory macrophage polarization[J]. Cell Signal,2017,33:107-121. [29]Li MP,Zhang YJ,Hu XL,et al. Association of CKIP-1 P21A polymorphism with risk of chronic heart failure in a Chinese population[J]. Oncotarget,2017,8(22):36545-36552. [30]Abraityte A,Aukrust P,Kou L,et al.T cell and monocyte/macrophage activation markers associate with adverse outcome,but give limited prognostic value in anemic patients with heart failure:results from RED-HF[J]. Clin Res Cardiol,2019,108(2):133-141. [31]El-Mahdy RI,Saleem TH,Essam OM,et al. Functional variants in the promoter region of macrophage migration inhibitory factor rs755622 gene (MIF G173C) among patients with heart failure:association with echocardiographic indices and disease severity[J]. Heart Lung,2021,50(1):92-100. [32]Leong DP,Mcmurray JJV,Joseph PG,et al. From ACE inhibitors/ARBs to ARNIs in coronary artery disease and heart failure(part 2/5)[J]. J Am Coll Cardiol,2019,74(5):683-698. [33]Johnson JA,Gong L,Whirl-Carrillo M,et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing[J]. Clin Pharmacol Ther,2011,90(4):625-62Genotype-Guided9. [34]Gage BF,Bass AR,Lin H,et al. Effect of warfarin dosing on clinical events and anticoagulation control among patients undergoing hip or knee arthroplasty the GIFT randomized clinical trial[J]. JAMA,2017,318(12):1115-1124. [35]Wu D,Li G,Deng M,et al. Associations between ADRB1 and CYP2D6 gene polymorphisms and the response to β-blocker therapy in hypertension[J]. J Int Med Res,2015,43(3):424-434. [36]Luzum JA,Sweet KM,Binkley PF,et al. CYP2D6 genetic variation and beta-blocker maintenance dose in patients with heart failure[J]. Pharm Res,2017,34(8):1615-1625. [37]隋小芳,卜宏魁,王凤玲,等. β受体阻滞剂基因导向治疗老年室上性心律失常疗效的相关性研究[J]. 中国老年保健医学,2015,13(2):35-38. [38]Hristova M,Stanilova S,Miteva L. Serum concentration of renin-angiotensin system components in association with ACE I/D polymorphism among hypertensive subjects in response to ACE inhibitor therapy[J]. Clin Exp Hypertens,2019,41(7):662-669. [39]Hamid S,Rhaleb IA,Kassem KM,et al. Role of kinins in hypertension and heart failure[J]. Pharmaceuticals(Basel),2020,13(11):347. [40]彭俊,黄自明,郭观华. HF患者ACE及CYP2D6遗传多态性与培哚普利疗效的关联性研究[J]. 中国临床新医学,2015,8(8):742-745. [41]赵平,赵淑萍,张沂,等. CYP11B2基因多态性与汉族、蒙古族原发性高血压的关系[J]. 心血管康复医学杂志,2020,29(4):401-405. [42]Sarhan NM,Shahin MH, El Rouby NM, et al. Effect of genetic and nongenetic factors on the clinical response to mineralocorticoid receptor antagonist therapy in Egyptians with heart failure[J]. Clin Transl Sci,2020,13(1):195-203. [43]Fontana V,de Faria AP,Barbaro NR,et al. Modulation of aldosterone levels by -344C/T CYP11B2 polymorphism and spironolactone use in resistant hypertension[J]. J Am Soc Hypertens,2014,8(3):146-151. [44]Turner ST,Chapman AB,Schwartz GL,et al. Effects of endothelial nitric oxide synthase, alpha-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide[J]. Am J Hypertens,2003,16(10):834-839. [45]Hoffmann M,Kleine-Weber H,Schroeder S,et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor[J]. Cell,2020,181(2):271-280. [46]Zheng YY,Ma YT,Zhang JY,et al. COVID-19 and the cardiovascular system[J]. Nat Rev Cardiol,2020,17(5):259-260. [47]Gómez J,Albaiceta GM,García-Clemente M,et al. Angiotensin-converting enzymes (ACE,ACE2) gene variants and COVID-19 outcome[J]. Gene,2020,762:145102. [48]Yamamoto N,Ariumi Y,Nishida N,et al. SARS-CoV-2 infections and COVID-19 mortalities strongly correlate with ACE1 I/D genotype[J]. Gene,2020,758:144944.